Bangkok Genomics Innovation PCL (BKK:BKGI) Other Current Assets: ฿156.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:BKGI Bangkok Genomics Innovation PCL BKK:BKGI
45 GF Score
Price ฿2.08
! 12 Warning Signs
View Full Analysis

What is Bangkok Genomics Innovation PCL Other Current Assets?

Bangkok Genomics Innovation PCL BKK:BKGI 45 Other Current Assets is ฿156.1 Mil as of Dec. 2025. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review.

Bangkok Genomics Innovation PCL's other current assets for the quarter that ended in Dec. 2025 was ฿156.1 Mil.

Bangkok Genomics Innovation PCL's quarterly other current assets increased from Jun. 2025 (฿26.1 Mil) to Sep. 2025 (฿35.6 Mil) and increased from Sep. 2025 (฿35.6 Mil) to Dec. 2025 (฿156.1Mil).

Bangkok Genomics Innovation PCL's annual other current assets increased from Dec. 2023 (฿6.8 Mil) to Dec. 2024 (฿22.6 Mil) increased from Dec. 2024 (฿22.6 Mil) to Dec. 2025 (฿156.1 Mil).


Bangkok Genomics Innovation PCL Other Current Assets Related Terms


Bangkok Genomics Innovation PCL Other Current Assets Historical Data

* Premium members only.

The historical data trend for Bangkok Genomics Innovation PCL's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL Other Current Assets Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial 0.53 2.90 6.76 22.60 156.10

Bangkok Genomics Innovation PCL Quarterly Data
Dec19 Dec20 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.60 24.13 26.13 35.59 156.10
BKK:BKGI
45GF Score
Bangkok Genomics Innovation PCL BKK:BKGI
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bangkok Genomics Innovation PCL Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of ฿156.1 Mil mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Other Current Assets of ฿156.1 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Bangkok Genomics Innovation PCL.
Is Bangkok Genomics Innovation PCL's Other Current Assets too high?
Bangkok Genomics Innovation PCL's current Other Current Assets is ฿156.1 Mil. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Other Current Assets compare to TMO and DHR?
Bangkok Genomics Innovation PCL's Other Current Assets of ฿156.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Medical Diagnostics & Research company?
A good Other Current Assets depends on the Medical Diagnostics & Research industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Bangkok Genomics Innovation PCL. Bangkok Genomics Innovation PCL's current Other Current Assets is ฿156.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Other Current Assets of ฿156.1 Mil. The current Other Current Assets is ฿156.1 Mil. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Other Current Assets is ฿156.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bangkok Genomics Innovation PCL Business Description

Address 3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score

Get the complete analysis for BKK:BKGI

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿2.08
Price